Ipsen reports full-year profits rise

1 March 2016
ipsen-logo-big

French pharmaceutical group Ipsen (EPA: IPN) has announced net profits of 190.7 million euros ($2017. 3 million) for the last financial year, 2015.

The figure shows a 23% increase on the previous 12-month period and a 25.3% increase in earnings per share to 2.78 euros. The board has proposed a dividend of 0.85 euros per share.

The annual report revealed sound cash flow generation with closing cash of 214.0 million euros. Full year group sales were up 10.4% to 1.44 billion euros up from 1.27 euros in 2014.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical